Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2024 Filed Feb 20, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 1,100 | $764.29 | $840,716.80 |
DisclosureSEC source: 0001415889-24-004339 · form4-02202024_040226.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,067,394 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $763.68 to $764.65, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), (27), (28), and (29) to this Form 4. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 1,400 | $762.26 | $1,067,165.40 |
DisclosureSEC source: 0001415889-24-004090 · form4-02162024_040201.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,068,494 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $762.22 to $762.41, inclusive. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 7,863 | $761.56 | $5,988,130.55 |
DisclosureSEC source: 0001415889-24-004090 · form4-02162024_040201.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,069,894 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $761.02 to $762.00, inclusive. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 41,053 | $760.19 | $31,208,121.12 |
DisclosureSEC source: 0001415889-24-004090 · form4-02162024_040201.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,077,757 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $760.00 to $760.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:19 UTC |
Norton JohnaEVP, Global Quality
|
GrantRestricted Stock Unit · Derivative | 1,308 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000036 · wk-form4_1707945531.xml · derivative · entry 5 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,308 Underlying: Common Stock · 1,308 shares Expires 2025-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:19 UTC |
Norton JohnaEVP, Global Quality
|
GrantCommon Stock | 1,668 | $737.26 | $1,229,749.68 |
DisclosureSEC source: 0000059478-24-000036 · wk-form4_1707945531.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,484 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC |
Weems AlonzoEVP, ERM & CECO
|
GrantRestricted Stock Unit · Derivative | 980 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000038 · wk-form4_1707945676.xml · derivative · entry 2 Weems Alonzo · CIK 0001869672 · EVP, ERM & CECO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 980 Underlying: Common Stock · 980 shares Expires 2025-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC |
Weems AlonzoEVP, ERM & CECO
|
GrantCommon Stock | 951 | $737.26 | $701,134.26 |
DisclosureSEC source: 0000059478-24-000038 · wk-form4_1707945676.xml · nonDerivative · entry 1 Weems Alonzo · CIK 0001869672 · EVP, ERM & CECO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,951 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:23 UTC |
Rau DiogoEVP & CIDO
|
GrantRestricted Stock Unit · Derivative | 3,269 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000040 · wk-form4_1707945812.xml · derivative · entry 2 Rau Diogo · CIK 0001860253 · EVP & CIDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,269 Underlying: Common Stock · 3,269 shares Expires 2025-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:25 UTC |
Jonsson PatrikEVP&Pres, LLY Dia&Obe, LLY USA
|
GrantRestricted Stock Unit · Derivative | 3,433 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000042 · wk-form4_1707945907.xml · derivative · entry 3 Jonsson Patrik · CIK 0001786054 · EVP&Pres, LLY Dia&Obe, LLY USA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,433 Underlying: Common Stock · 3,433 shares Expires 2025-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:25 UTC |
Jonsson PatrikEVP&Pres, LLY Dia&Obe, LLY USA
|
GrantCommon Stock | 5,362 | $737.26 | $3,953,188.12 |
DisclosureSEC source: 0000059478-24-000042 · wk-form4_1707945907.xml · nonDerivative · entry 1 Jonsson Patrik · CIK 0001786054 · EVP&Pres, LLY Dia&Obe, LLY USA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,583 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:27 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
GrantRestricted Stock Unit · Derivative | 2,861 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000044 · wk-form4_1707946006.xml · derivative · entry 3 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,861 Underlying: Common Stock · 2,861 shares Expires 2025-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:27 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
GrantCommon Stock | 2,821 | $737.26 | $2,079,810.46 |
DisclosureSEC source: 0000059478-24-000044 · wk-form4_1707946006.xml · nonDerivative · entry 1 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,682 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:29 UTC |
Yuffa IlyaEVP & President, LLY Int'l
|
GrantRestricted Stock Unit · Derivative | 3,269 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000046 · wk-form4_1707946126.xml · derivative · entry 2 Yuffa Ilya · CIK 0001826001 · EVP & President, LLY Int'l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,269 Underlying: Common Stock · 3,269 shares Expires 2025-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:29 UTC |
Yuffa IlyaEVP & President, LLY Int'l
|
GrantCommon Stock | 4,790 | $737.26 | $3,531,475.40 |
DisclosureSEC source: 0000059478-24-000046 · wk-form4_1707946126.xml · nonDerivative · entry 1 Yuffa Ilya · CIK 0001826001 · EVP & President, LLY Int'l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,802 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:31 UTC |
Ricks David ADirector · President, Chair, and CEO
|
GrantRestricted Stock Unit · Derivative | 26,561 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000048 · wk-form4_1707946275.xml · derivative · entry 5 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,561 Underlying: Common Stock · 26,561 shares Expires 2025-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:31 UTC |
Ricks David ADirector · President, Chair, and CEO
|
GrantCommon Stock | 38,392 | $737.26 | $28,304,885.92 |
DisclosureSEC source: 0000059478-24-000048 · wk-form4_1707946275.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 479,250 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:34 UTC |
Hakim AnatEVP, GC & Secretary
|
GrantRestricted Stock Unit · Derivative | 4,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000050 · wk-form4_1707946408.xml · derivative · entry 2 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,904 Underlying: Common Stock · 4,904 shares Expires 2025-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:34 UTC |
Hakim AnatEVP, GC & Secretary
|
GrantCommon Stock | 5,815 | $737.26 | $4,287,166.90 |
DisclosureSEC source: 0000059478-24-000050 · wk-form4_1707946408.xml · nonDerivative · entry 1 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,479 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:36 UTC |
Skovronsky DanielEVP, CSO & Pres. LRL & LLY Imm
|
GrantRestricted Stock Unit · Derivative | 8,989 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000052 · wk-form4_1707946554.xml · derivative · entry 3 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,989 Underlying: Common Stock · 8,989 shares Expires 2025-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:36 UTC |
Skovronsky DanielEVP, CSO & Pres. LRL & LLY Imm
|
GrantCommon Stock | 12,910 | $737.26 | $9,518,026.60 |
DisclosureSEC source: 0000059478-24-000052 · wk-form4_1707946554.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,738 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:38 UTC |
Ashkenazi AnatEVP & CFO
|
GrantRestricted Stock Unit · Derivative | 4,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000054 · wk-form4_1707946682.xml · derivative · entry 3 Ashkenazi Anat · CIK 0001761679 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,904 Underlying: Common Stock · 4,904 shares Expires 2025-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:38 UTC |
Ashkenazi AnatEVP & CFO
|
GrantCommon Stock | 4,210 | $737.26 | $3,103,864.60 |
DisclosureSEC source: 0000059478-24-000054 · wk-form4_1707946682.xml · nonDerivative · entry 1 Ashkenazi Anat · CIK 0001761679 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,330 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:39 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
GrantCommon Stock | 1,254 | $737.26 | $924,524.04 |
DisclosureSEC source: 0000059478-24-000056 · wk-form4_1707946769.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,630 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:41 UTC |
Van Naarden JacobEVP & Pres., Loxo@Lilly
|
GrantRestricted Stock Unit · Derivative | 3,023 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000058 · wk-form4_1707946860.xml · derivative · entry 3 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Loxo@Lilly 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,023 Underlying: Common Stock · 3,023 shares Expires 2025-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:41 UTC |
Van Naarden JacobEVP & Pres., Loxo@Lilly
|
GrantCommon Stock | 2,369 | $737.26 | $1,746,568.94 |
DisclosureSEC source: 0000059478-24-000058 · wk-form4_1707946860.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Loxo@Lilly 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,147 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:43 UTC |
Dozier EricEVP, HR & Diversity
|
GrantCommon Stock | 1,336 | $737.26 | $984,979.36 |
DisclosureSEC source: 0000059478-24-000060 · wk-form4_1707946973.xml · nonDerivative · entry 2 Dozier Eric · CIK 0001955972 · EVP, HR & Diversity 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,190 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:43 UTC |
Dozier EricEVP, HR & Diversity
|
GiftCommon Stock | 408 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000060 · wk-form4_1707946973.xml · nonDerivative · entry 1 Dozier Eric · CIK 0001955972 · EVP, HR & Diversity 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,854 F1 · shares: Reflects the gift of common stock to a charitable donor advised fund. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:44 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
GrantRestricted Stock Unit · Derivative | 3,269 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000062 · wk-form4_1707947068.xml · derivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,269 Underlying: Common Stock · 3,269 shares Expires 2025-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:44 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
GrantCommon Stock | 5,363 | $737.26 | $3,953,925.38 |
DisclosureSEC source: 0000059478-24-000062 · wk-form4_1707947068.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,569 Read SEC document |
| February 12, 2024 Filed Mar 11, 2024 20:27 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
GrantRestricted Stock Unit · Derivative | 186 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000082 · wk-form4_1710188730.xml · derivative · entry 4 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186 Underlying: Common Stock · 186 shares Expires 2027-02-16 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. These grants were inadvertently omitted from the reporting person's Form 4 filed on February 14, 2024. Read SEC document |
| February 12, 2024 Filed Mar 11, 2024 20:27 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
GrantRestricted Stock Unit · Derivative | 184 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000082 · wk-form4_1710188730.xml · derivative · entry 3 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184 Underlying: Common Stock · 184 shares Expires 2026-02-16 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. These grants were inadvertently omitted from the reporting person's Form 4 filed on February 14, 2024. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 2,300 | $745.24 | $1,714,052.00 |
DisclosureSEC source: 0001415889-24-003359 · form4-02122024_040201.xml · nonDerivative · entry 6 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,118,810 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $745.04 to $745.53, inclusive. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 1,867 | $744.53 | $1,390,035.64 |
DisclosureSEC source: 0001415889-24-003359 · form4-02122024_040201.xml · nonDerivative · entry 5 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,121,110 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $744.04 to $744.90, inclusive. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 1,500 | $743.58 | $1,115,364.00 |
DisclosureSEC source: 0001415889-24-003359 · form4-02122024_040201.xml · nonDerivative · entry 4 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,122,977 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $743.00 to $743.895, inclusive. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 4,792 | $742.22 | $3,556,703.86 |
DisclosureSEC source: 0001415889-24-003359 · form4-02122024_040201.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,124,477 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $742.00 to $742.57, inclusive. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 30,253 | $741.41 | $22,429,937.24 |
DisclosureSEC source: 0001415889-24-003359 · form4-02122024_040201.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,129,269 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $741.00 to $741.995, inclusive. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 165,545 | $740.27 | $122,547,334.97 |
DisclosureSEC source: 0001415889-24-003359 · form4-02122024_040201.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,159,522 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $740.00 to $740.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), and (6) to this Form 4. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:05 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 8,743 | $740.06 | $6,470,335.84 |
DisclosureSEC source: 0001415889-24-003164 · form4-02092024_040201.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,325,067 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $740.00 to $740.38, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:16 UTC |
Ricks David ADirector · President, Chair, and CEO
|
GiftCommon Stock | 956 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000034 · wk-form4_1707772578.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,858 F1 · shares: On February 8, 2024, the Reporting Person transferred 956 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person's wife is the trustee and the Reporting Person's wife and children are beneficiaries. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:20 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,124 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000013 · wk-form4_1706908818.xml · derivative · entry 3 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,124 shares Expires 2024-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:20 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
Tax withholdingCommon Stock | 1,844 | $645.61 | $1,190,504.84 |
DisclosureSEC source: 0000059478-24-000013 · wk-form4_1706908818.xml · nonDerivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,206 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:20 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
Exercise / conversionCommon Stock | 4,124 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000013 · wk-form4_1706908818.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:22 UTC |
Van Naarden JacobEVP & Pres., Loxo@Lilly
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,618 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000015 · wk-form4_1706908964.xml · derivative · entry 4 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Loxo@Lilly 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,618 shares Expires 2024-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:22 UTC |
Van Naarden JacobEVP & Pres., Loxo@Lilly
|
Tax withholdingCommon Stock | 1,685 | $645.61 | $1,087,852.85 |
DisclosureSEC source: 0000059478-24-000015 · wk-form4_1706908964.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Loxo@Lilly 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,778 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:22 UTC |
Van Naarden JacobEVP & Pres., Loxo@Lilly
|
Exercise / conversionCommon Stock | 3,618 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000015 · wk-form4_1706908964.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Loxo@Lilly 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:24 UTC |
Norton JohnaEVP, Global Quality
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,268 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000017 · wk-form4_1706909035.xml · derivative · entry 6 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,268 shares Expires 2024-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:24 UTC |
Norton JohnaEVP, Global Quality
|
Tax withholdingCommon Stock | 566 | $645.61 | $365,415.26 |
DisclosureSEC source: 0000059478-24-000017 · wk-form4_1706909035.xml · nonDerivative · entry 2 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,816 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:24 UTC |
Norton JohnaEVP, Global Quality
|
Exercise / conversionCommon Stock | 1,268 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000017 · wk-form4_1706909035.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:25 UTC |
Skovronsky DanielEVP, CSO & Pres. LRL & LLY Imm
|
Exercise / conversionRestricted Stock Unit · Derivative | 9,941 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000019 · wk-form4_1706909126.xml · derivative · entry 4 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,941 shares Expires 2024-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.